Ozempic vs Wegovy
Ozempic and Wegovy are both semaglutide — the same molecule, made by the same company (Novo Nordisk). The difference is the approved indication and dosing. Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management. This is one of the most searched peptide comparisons, and the confusion is understandable.
Semaglutide
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Semaglutide
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
| Category | Semaglutide | Semaglutide |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide (identical molecule) |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA-Approved For | Type 2 diabetes (as adjunct to diet and exercise) | Chronic weight management (BMI ≥30, or ≥27 with comorbidity) |
| Maximum Dose | 2.0 mg once weekly | 2.4 mg once weekly |
| Dose Escalation | 0.25mg → 0.5mg → 1.0mg → 2.0mg over ~8 weeks | 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg over ~16 weeks |
| Key Trial Program | SUSTAIN (7 Phase III trials in T2DM) | STEP (4+ Phase III trials in obesity) |
| Weight Loss (Trial Data) | ~5-7% body weight (at diabetes doses) | ~15% body weight at 2.4mg (STEP 1, 68 weeks) |
| Cardiovascular Data | SUSTAIN-6: reduced MACE in T2DM | SELECT: 20% MACE reduction in obesity without diabetes |
| Oral Form Available | Yes — Rybelsus (oral semaglutide 7mg/14mg) | Yes — oral Wegovy 25mg (approved Jan 2026) |
| Insurance Coverage | Broader — most insurance covers for T2DM | More limited — many insurers exclude weight management |
| Cost Without Insurance | ~$900–$1,100/month | ~$1,300–$1,400/month |
| Can One Substitute for the Other? | Off-label use for weight loss is common but not FDA-approved | Not indicated for diabetes unless patient also qualifies |
Summary
The bottom line: Ozempic and Wegovy are the same drug at different doses for different conditions. Wegovy goes to a higher maximum dose (2.4mg vs 2.0mg) with a slower escalation, optimized for weight loss. Ozempic at its diabetes doses produces modest weight loss (~5-7%), while Wegovy's higher dose produces dramatic weight loss (~15%). Many patients are prescribed Ozempic off-label for weight management when insurance won't cover Wegovy — this is a cost-driven workaround, not a clinical recommendation. The SELECT trial (Wegovy) showed cardiovascular benefit even in non-diabetic obesity, which Ozempic's SUSTAIN-6 trial only demonstrated in diabetic patients. If your primary goal is weight management, Wegovy at 2.4mg has the strongest evidence. If you have type 2 diabetes, Ozempic is the appropriate choice. If cost is the barrier, compounded semaglutide at equivalent doses is an alternative worth discussing with your clinician.
These peptides are often used together. See our stack profiles for combination details.